GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AREV Life Sciences Global Corp (OTCPK:AREVF) » Definitions » Cash-to-Debt

AREV Life Sciences Global (AREV Life Sciences Global) Cash-to-Debt : 0.01 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is AREV Life Sciences Global Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AREV Life Sciences Global's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, AREV Life Sciences Global couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for AREV Life Sciences Global's Cash-to-Debt or its related term are showing as below:

AREVF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0.23   Max: No Debt
Current: 0.01

During the past 13 years, AREV Life Sciences Global's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.23.

AREVF's Cash-to-Debt is ranked worse than
97.15% of 1051 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs AREVF: 0.01

AREV Life Sciences Global Cash-to-Debt Historical Data

The historical data trend for AREV Life Sciences Global's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AREV Life Sciences Global Cash-to-Debt Chart

AREV Life Sciences Global Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.05 0.41 2.09 -

AREV Life Sciences Global Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 - 0.64 0.05 0.01

Competitive Comparison of AREV Life Sciences Global's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, AREV Life Sciences Global's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AREV Life Sciences Global's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AREV Life Sciences Global's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AREV Life Sciences Global's Cash-to-Debt falls into.



AREV Life Sciences Global Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AREV Life Sciences Global's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

AREV Life Sciences Global's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AREV Life Sciences Global  (OTCPK:AREVF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


AREV Life Sciences Global Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AREV Life Sciences Global's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


AREV Life Sciences Global (AREV Life Sciences Global) Business Description

Traded in Other Exchanges
N/A
Address
91 Golden Drive, Unit 18, Coquitlam, BC, CAN, V3K 6R2
AREV Life Sciences Global Corp is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. The Company's focuses on dedication to generate revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic co-morbidities.

AREV Life Sciences Global (AREV Life Sciences Global) Headlines